eligibility_summary
Adults ≥18 with recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer (HGS, endometrioid, clear cell, or mixed ≥50%), any platinum status, measurable and/or CA‑125–evaluable disease, ECOG 0–1, adequate organ function, consent + blood/archival tissue, Mayo follow‑up, tetanus vax, possible apheresis line. Exclude: pregnancy/lactation/no contraception, prior PD‑1/PD‑L1, recent therapy, symptomatic/bulky disease, major comorbidity, uncontrolled HIV, active HBV/HCV unless controlled, immune pneumonitis/ILD, active autoimmune disease ≤2y, serious infection, other active malignancy, recent MI/CHF, systemic immunosuppression, prior allogeneic SCT.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: 1) Multi-epitope folate receptor alpha–loaded dendritic cell vaccine (FRαDC, autologous cellular vaccine). Patient leukocytes are differentiated into dendritic cells and pulsed with FRα peptides, intradermal dosing. MOA: professional antigen presentation (MHC I/II) to prime/expand FRα-specific CD8+ cytotoxic and CD4+ T cells, boosting Th1 (IFNγ) and Th17 (IL-17) responses and anti-FRα IgG, leading to killing of FRα-positive ovarian tumor cells. 2) Pembrolizumab (Keytruda, anti–PD-1 monoclonal antibody checkpoint inhibitor) IV. MOA: blocks PD-1 on T cells to prevent PD-1/PD-L1 inhibitory signaling and sustain tumor-specific T-cell activity. Cells/pathways targeted: FRα on tumor cells, dendritic cells, CD8+ T cells, Th1/Th17 CD4+ T cells, B-cell humoral responses, PD-1/PD-L1 checkpoint, tumor immune microenvironment.